Healthcare Industry News:  Ash Access Technology 


 News Release - January 17, 2008

Ash Access Technology, Inc. Partners With AngioDynamics to Launch Innovative Central Venous Catheter for Hemodialysis

Novel Catheter Design Promises Enhanced Flow With Fewer Complications

LAFAYETTE, IN--(Healthcare Sales & Marketing Network)--Jan 17, 2008 -- Ash Access Technology, Inc., an integrated specialty pharmaceutical / medical device company engaged in the development and commercialization of proprietary products and devices to improve vascular access outcomes, announced today the creation of a strategic commercial partnership with AngioDynamics to launch Centros(TM), an innovative self-centering, tunneled hemodialysis access catheter. Ash Access Technology, Inc. agreed to give exclusive worldwide rights to manufacture and market the Centros dialysis catheter to Queensbury, NY-based AngioDynamics.

Designed by Stephen R. Ash, MD, FACP, Centros represents a new approach for central venous dialysis catheters (CVDC). The distal end of the catheter has a unique curved configuration; placed in the superior vena cava (SVC), its curved tips keep the ports of the catheter centered in the SVC, away from the vein walls. The tips of the catheter are not placed in the atrium, but in the lower third of the SVC. The United States Food and Drug Administration granted its 510(k) clearance for Centros in June 2007.

"Based on our clinical trials with Centros, we believe that our novel design will improve placement and enable excellent, uncompromised blood flow for a longer period than other, currently available dialysis catheters," said Dr. Ash. "Patients would therefore benefit from a faster procedure, potentially enhanced flow and fewer interventions, which are often required for clots, sheathing or other complications."

Dr. Ash, Board Chairman and Director of R&D at Ash Access Technology, a worldwide thought leader in the field of hemodialysis access and a well-published author and holder of numerous patents, is renowned as the inventor of the original split tip dialysis catheter. He will present data from a United States preliminary clinical study of the Centros catheter on Wednesday, January 23 at the International Symposium for Endovascular Therapy in Hollywood, Florida.

"We are excited about the benefits Centros can bring to patients requiring the use of a tunneled catheter for hemodialysis. Its unique design and preliminary study results hold tremendous promise for enhanced flow and fewer complications," said Bob Truitt, Ash Access Technology President and CEO. "We feel privileged to be partnering with AngioDynamics to bring Centros to market. We feel their drive for innovation, proven track record of success in the dialysis business and strong customer relationships will be an excellent fit with our organization."

About Ash Access Technology, Inc.

Ash Access Technology, Inc. is a privately held specialty pharmaceutical / medical device company focused on the development and commercialization of proprietary products and devices to improve vascular access outcomes. The Company's diverse product portfolio includes innovative hemodialysis and peritoneal dialysis catheters and a unique antimicrobial / antithrombotic solution, Zuragen™, being developed for the prevention and treatment of catheter related bloodstream infection (CRBSI). Ash Access Technology is located in Lafayette, Indiana in the INOK Business Center.

Safe Harbor

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as other risk factors may affect the actual results achieved by the Company.

Source: Ash Access Technology

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.